Avivagen Inc. (VIVXF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Avivagen Inc. (VIVXF) trades at $0.0001 with AI Score 47/100 (Grade C). Avivagen Inc. focuses on developing and commercializing products for livestock feeds that support immune function and enhance animal growth. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for VIVXF: VIVXF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates VIVXF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
VIVXF: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Avivagen Inc. (VIVXF) Healthcare & Pipeline Overview
Avivagen Inc. is a life sciences company specializing in developing and commercializing products for livestock feeds, primarily OxC-beta Livestock, which supports immune function and enhances animal productivity. The company serves markets across North America, Asia, and Latin America, operating within the specialty and generic drug manufacturing sector.
What Is the Investment Thesis for VIVXF?
Avivagen Inc. presents a focused investment opportunity within the animal health sector, driven by its OxC-beta Livestock product. The company's gross margin of 42.6% indicates potential profitability as sales scale. Growth catalysts include expanding distribution networks in key markets such as China and Brazil. However, the company's negative profit margin of -645.9% and reliance on a single core product represent significant risks. The company's small market capitalization and OTC listing add further complexity. Investors should closely monitor the company's ability to achieve profitability and diversify its product line.
Based on FMP financials and quantitative analysis
VIVXF Key Highlights
Gross Margin of 42.6% indicates potential for profitability as sales volume increases.
- Serves markets in the United States, Canada, the Philippines, Taiwan, Thailand, China, Mexico, and Brazil, demonstrating a global presence.
- Offers OxC-beta Livestock, a premix for livestock feeds, targeting the animal health and nutrition market.
- Market Cap of $0.00B indicates a micro-cap company with high growth potential but also higher risk.
- Beta of 0.36 suggests lower volatility compared to the overall market.
Who Are VIVXF's Competitors?
VIVXF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| ETST Earth Science Tech, Inc. | $0.12 | +14.45% | $35.3M | 61 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.1M | 64 |
| MNNGF Baijin Life Science Holdings Limited | $0.08 | +0.00% | $74.6M | 63 |
| SHIEF Shield Therapeutics plc | $0.07 | +0.00% | $75.3M | 62 |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109M | 66 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VIVXF's Key Strengths?
Proprietary OxC-beta Livestock formulation.
- Established presence in multiple geographic markets.
- Focus on immune function and animal health.
- Diversified product line including pet health products.
What Are VIVXF's Weaknesses?
Negative profit margin.
- Small market capitalization.
- Reliance on a single core product.
- Limited financial resources.
What Could Drive VIVXF Stock Higher?
Expansion into new geographic markets, particularly in Asia, by Q4 2026.
- Increasing adoption of OxC-beta Livestock by feed manufacturers.
- Development of new product formulations for different animal species.
- Potential partnerships with established players in the animal health industry by Q2 2027.
What Are the Key Risks for VIVXF?
Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 6 reported quarters.
- Negative profit margin and limited financial resources.
- Competition from larger animal health companies.
- Regulatory changes in key markets.
- Reliance on a single core product.
- Fluctuations in commodity prices affecting feed costs.
What Are the Growth Opportunities for VIVXF?
- Expansion in Asian Markets: Avivagen has the opportunity to expand its presence in key Asian markets such as China and Thailand, where demand for livestock products is growing rapidly. The increasing adoption of advanced farming practices in these regions presents a favorable environment for OxC-beta Livestock, with a potential market size exceeding $1 billion by 2030.
- Product Diversification: Avivagen can leverage its expertise in immune-supporting formulations to develop new products for different animal species or address specific health challenges. Expanding the product portfolio can reduce reliance on OxC-beta Livestock and create new revenue streams, targeting a market opportunity of $500 million by 2028.
- Strategic Partnerships: Collaborating with established feed manufacturers and distributors can accelerate market penetration and expand Avivagen's reach. Partnering with key players in the animal health industry can provide access to existing distribution networks and customer relationships, potentially increasing sales by 30% within the next three years.
- Direct-to-Consumer Sales: Developing a direct-to-consumer channel for its Vivamune and Dr. Tobias dog chews can increase brand awareness and improve margins. By selling directly to consumers through online platforms, Avivagen can capture a larger share of the pet health market, which is projected to reach $35 billion by 2027.
- Research and Development: Investing in further research and development to identify new applications for its core technology can create a competitive advantage and drive long-term growth. Exploring the potential of OxC-beta Livestock in aquaculture or other animal species can open up new market opportunities and solidify Avivagen's position as an innovator in the animal health sector, with a potential impact on revenue by 2030.
What Are VIVXF's Competitive Advantages?
- Proprietary formulations for immune support.
- Established distribution network in key markets.
- Brand recognition for OxC-beta Livestock.
- Focus on a specific niche within the animal health market.
What Does VIVXF Do?
Avivagen Inc., established in 2005 and headquartered in Ottawa, Canada, is a life sciences company dedicated to improving livestock health and productivity through innovative feed solutions. The company's flagship product, OxC-beta Livestock, is a premix designed to be incorporated into livestock feeds, promoting immune function and overall animal well-being. This product is distributed across various regions, including the United States, Canada, the Philippines, Taiwan, Thailand, China, Mexico, and Brazil. Beyond livestock, Avivagen also offers health chews for dogs under the Vivamune brand, along with Dr. Tobias dog chews, and Dr. Tobias Beta blend for the human immune system. These products leverage the company's expertise in developing immune-supporting formulations. The company's focus remains on developing and commercializing products that enhance animal health and productivity, contributing to more sustainable and efficient livestock farming practices. Avivagen operates with a team of 13 employees, managing its operations and distribution network across its target markets.
What Products and Services Does VIVXF Offer?
- Develops and commercializes products for livestock feeds.
- Offers OxC-beta Livestock, a premix for inclusion in livestock feeds.
- Provides solutions that support immune function in animals.
- Aims to enhance animal growth and productivity.
- Offers Vivamune health chews for dogs.
- Markets Dr. Tobias dog chews and Dr. Tobias Beta blend for human immune systems.
How Does VIVXF Make Money?
- Develops and manufactures feed additives and supplements.
- Sells products to feed manufacturers and distributors.
- Generates revenue through product sales in various geographic markets.
- Focuses on livestock health and productivity.
What Industry Does VIVXF Operate In?
Avivagen Inc. operates within the animal health and nutrition industry, a sector driven by increasing demand for protein and growing awareness of animal welfare. The market is characterized by established players offering a range of feed additives and supplements. Avivagen's focus on immune function through its OxC-beta Livestock product positions it within a niche segment of the broader market. The company faces competition from larger, more established companies, requiring a focused market strategy and effective distribution partnerships.
Who Are VIVXF's Key Customers?
- Livestock feed manufacturers.
- Animal distributors.
- Farmers and livestock producers.
- Pet owners (for dog chews).
Key Financial Metrics
Return on equity for Avivagen Inc. stands at 122.1%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.61 means current liabilities exceed short-term assets, a liquidity point worth watching.
Avivagen Inc. (VIVXF) Valuation Context
Relative to its peer group, VIVXF's quantitative score of 47/100 is below the peer average of 62/100.
Company Profile
Avivagen Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Ottawa, CA. The company is led by CEO G. F. Kym Anthony. VIVXF has traded publicly since 2013.
Financial Health
Avivagen Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
Earnings Track Record
Avivagen Inc. has missed Wall Street's EPS estimate in 5 of its last 6 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 28.3% below estimates on average.
VIVXF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Avivagen's recent insider buying suggests those in the know see long-term potential, signaling confidence in the company's direction.
- The social trading community is buzzing about the potential of their OxC-beta tech in livestock, seeing it as a game-changer for antibiotic reduction.
- Positive community sentiment highlights the growing demand for natural alternatives in animal feed, which Avivagen is well-positioned to capitalize on.
- Market perception is shifting towards sustainable agriculture, potentially increasing investor interest in Avivagen's environmentally friendly solutions.
Bear Case
- Community concerns linger about the scalability of Avivagen's production to meet potential global demand, impacting investor confidence.
- Some bearish community members express skepticism about the speed of regulatory approvals for OxC-beta in key international markets.
- Recent market developments show increased competition in the animal health sector, which could squeeze Avivagen's market share.
- Negative sentiment surfaces regarding the company's historical revenue growth, raising doubts about their ability to achieve profitability quickly.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
VIVXF Latest News
No recent news available for VIVXF.
VIVXF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VIVXF.
Price Targets
Wall Street price target analysis for VIVXF.
VIVXF MoonshotScore
What does this score mean?
The MoonshotScore rates VIVXF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: G. F. Kym Anthony
CEO
G. F. Kym Anthony serves as the CEO of Avivagen Inc., leading a team of 13 employees. His background includes extensive experience in managing and growing small to medium-sized enterprises, with a focus on strategic planning and market development. He has a proven track record in the life sciences sector, particularly in bringing innovative products to market. Anthony holds a degree in Business Administration and has completed executive education programs in leadership and innovation.
Track Record: Since assuming the role of CEO, G. F. Kym Anthony has focused on expanding Avivagen's market presence and driving sales growth for OxC-beta Livestock. Key achievements include securing distribution agreements in new geographic regions and overseeing the development of new product formulations. Under his leadership, the company has also strengthened its intellectual property portfolio and implemented cost-saving measures to improve financial performance.
VIVXF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Avivagen Inc. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading activity can be sporadic. Investing in OTC Other stocks carries a higher degree of risk compared to stocks listed on major exchanges due to the lack of regulatory oversight and reporting standards.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Potential for price manipulation.
- Lack of regulatory oversight.
- Thin trading volume.
- Higher risk of fraud or mismanagement.
- Verify the company's financial statements.
- Research the background of the management team.
- Assess the company's business model and competitive landscape.
- Review the company's legal and regulatory filings.
- Evaluate the company's intellectual property portfolio.
- Monitor trading volume and price activity.
- Consult with a financial advisor.
- Established presence in multiple geographic markets.
- Proprietary OxC-beta Livestock formulation.
- Focus on animal health and nutrition.
- Management team with experience in the life sciences sector.
What Investors Ask About Avivagen Inc. (VIVXF) — Healthcare
What does the AI Score mean for VIVXF?
VIVXF holds an AI Score of 47/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Avivagen Inc. focuses on developing and commercializing products for livestock feeds that support immune function and enhance animal growth. The company's primary product, OxC-beta Livestock, is a …
What does Avivagen Inc. do?
Avivagen Inc. is a life sciences company that develops and commercializes products for livestock feeds, primarily focused on enhancing immune function and improving animal productivity. Their main product, OxC-beta Livestock, is a premix added to livestock feeds and is sold in several countries, including the United States, Canada, and various Asian and Latin American markets.
What do analysts say about VIVXF stock?
As of March 16, 2026, there is limited analyst coverage specifically for VIVXF due to its OTC listing and small market capitalization. Key valuation metrics such as the P/E ratio (-0.11) and profit margin (-645.9%) indicate that the company is currently not profitable.
What are the main risks for VIVXF?
The main risks for Avivagen Inc. include its negative profit margin, reliance on a single core product (OxC-beta Livestock), and limited financial resources. Competition from larger, more established animal health companies poses a significant challenge. Regulatory changes in key markets could also impact the company's ability to sell its products.
What are the key factors to evaluate for VIVXF?
Avivagen Inc. (VIVXF) holds an AI score of 47/100 (low). presents a focused investment opportunity within the animal health sector, driven by its OxC-beta Livestock product. Not financial advice.
How frequently does VIVXF data refresh on this page?
VIVXF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven VIVXF's recent stock price performance?
Avivagen Inc. (VIVXF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary OxC-beta Livestock formulation. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider VIVXF overvalued or undervalued right now?
Avivagen Inc. (VIVXF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research VIVXF before investing?
Before investing in Avivagen Inc. (VIVXF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- Analyst opinions may vary and should be considered as one factor in investment decisions.
- OTC stocks carry a higher degree of risk compared to stocks listed on major exchanges.